1. Scrip
  2. >>Business

Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth

Single-Dose Malaria Drug Moves To Phase II

 
• By Vibha Ravi

Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.

Pill Bottle Labeled Biosimilars
Zydus Makes Gains In Biosimilars • Source: Alamy

On 24 May 2021, Zydus Cadila launched the world's first antibody drug conjugate (ADC) biosimilar to Roche Holding AG/Genentech, Inc.’s Kadcyla (trastuzumab emtansine), under the name Ujvira to treat early and advanced HER2-positive breast cancer in India.

With that, the company stepped up its biosimilars portfolio to 12 products and gained the top spot in the Indian domestic market for biosimilars, managing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.